Mode
Text Size
Log in / Sign up

Systematic review of multimodal machine learning models for heart failure classification and prognosis prediction

Systematic review of multimodal machine learning models for heart failure classification and prognos…
Photo by Growtika / Unsplash
Key Takeaway
Note inconsistent reporting and lack of prospective validation in this systematic review of multimodal machine learning for heart failure.

This systematic review evaluates the utility of multimodal machine learning models compared to unimodal approaches in the context of heart failure. The analysis encompasses 15 included studies, though the specific population and setting were not reported. The primary focus was on the performance of these models for secondary outcomes including HF classification and prognosis prediction. No primary outcome was explicitly defined in the source text.

The synthesized findings indicate that multimodal models demonstrated superior performance relative to unimodal approaches. Specifically, area under the receiver operating characteristic curve values frequently exceeding 80% and reaching as high as 98.2% were observed. It is important to note that absolute numbers, p-values, and confidence intervals were not reported for these results. Furthermore, no safety data, adverse events, or discontinuations were documented in the included studies.

The authors identify several critical limitations that constrain the current evidence base. These include inconsistent reporting of performance metrics and their 95% confidence intervals, limited external validation, and a near absence of prospective studies. Additionally, there is a deficiency in integrating genetic or 'omics' information with conventional data. Funding sources and potential conflicts of interest were not reported.

Given the lack of prospective validation and inconsistent metric reporting, the clinical relevance of these findings remains uncertain. Practitioners should interpret these results with caution, recognizing that the evidence does not yet support the routine implementation of such models without further prospective investigation.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedApr 2026
View Original Abstract ↓
IntroductionHeart failure (HF) is a global medical condition marked by substantial morbidity, mortality, and healthcare costs with complex pathophysiology and variation in definitions. Machine learning (ML) has emerged as a promising approach to improve HF classification and risk prediction by leveraging various data sources. This study aims to present the current state-of-the-art multimodal ML models for HF classification and prognosis prediction, focusing on their modalities, performance, and clinical utility.MethodsFollowing PRISMA guidelines and registered with PROSPERO (CRD420250654631), this review searched across four electronic databases (November 2014 – November 2024) and identified 284 unique records, of which 15 were included in the final synthesis. The quality of the studies was evaluated using QUADAS-2 and QUAPAS.ResultsOur results showed that the two most common multimodal combinations were tabular-image and tabular-text. The algorithms of the models included convolutional neural networks for image data, transformer-based approaches for text, with well-known fused techniques (early, middle, late fusion). Overall, multimodal models demonstrated superior performance compared to unimodal approaches, achieving area under the receiver operating characteristic curve values frequently exceeding 80% and reaching as high as 98.2%.ConclusionDespite promising results, challenges include inconsistent reporting of performance metrics and their 95% confidence intervals, limited external validation, a near absence of prospective studies, and a deficiency in integrating genetic or 'omics' information with conventional data. These challenges must be addressed to promote clinical adoption and future researchSystematic Review Registrationhttps://www.crd.york.ac.uk/PROSPERO/view/CRD420250654631, identifier CRD420250654631.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.